Findings from Evidera Provides New Data on Heart Attack (Clinical and economic outcomes among elderly myocardial infarction survivors in the United…

Findings from Evidera Provides New Data on Heart Attack (Clinical and economic outcomes among elderly myocardial infarction survivors in the United States)

By a News Reporter-Staff News Editor at Insurance Weekly News -- Researchers detail new data in Heart Disorders and Diseases - Heart Attack. According to news reporting out of Waltham, Massachusetts, by VerticalNews editors, research stated, "Longitudinal data are limited regarding outcomes and costs beyond 1 year after acute myocardial infarction (MI) among elderly (>= 65 years old) US patients. This study examined long-term outcomes and healthcare costs among elderly MI survivors."

Financial support for this research came from AstraZeneca.

Our news journalists obtained a quote from the research from Evidera, "Retrospective analysis of 2002-2009 Medicare healthcare claims (5% random sample). Patients were >= 65 years old and survived >= 1 year without recurrent MI after MI hospitalization. Mortality, incidence of hospitalizations for stroke, major bleeding, MI, a composite endpoint (death, MI, or stroke), and nonpharmacy healthcare costs were determined. Eligible patients included 16 244 STEMI, 34 576 NSTEMI, and 3109 unspecified MI. NSTEMI and unspecified MI patients had significantly higher prevalence of comorbidities than STEMI patients, except for hypertension and dyslipidemia. MI incidence declined 36% over the follow-up (3.82/100 person-years [PY] to 2.45/100 PY). Mortality, stroke, and bleeding decreased until the third year of follow-up and then increased. NSTEMI and unspecified MI patients had a significantly higher incidence of death, MI, the composite, and bleeding than STEMI patients throughout follow-up. All-cause inpatient costs during follow-up were 2.6- and 1.9-fold higher than baseline for STEMI and NSTEMI, respectively; cardiovascular-related inpatient costs were 3.5- and 2.2-fold higher, respectively. Risks of mortality and cardiovascular events remain high in a Medicare population surviving >1 year after a MI. Continuing healthcare costs are doubled over pre-MI levels up to 5 years after an MI."

According to the news editors, the research concluded: "Secondary prevention measures beyond the acute post-MI period may be indicated to reduce risk and cost in this chronic disease phase."

For more information on this research see: Clinical and economic outcomes among elderly myocardial infarction survivors in the United States. Cardiovascular Therapeutics, 2016;34(6):450-459. Cardiovascular Therapeutics can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Cardiovascular Therapeutics - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1755-5922)

Our news journalists report that additional information may be obtained by contacting P. Hunt, Evidera, Waltham, MA 02451, United States. Additional authors for this research include M. Stokes, S. Johansson, C. Mellstrom, E. Magnuson, D.J. Cohen and P. Hunt.

Keywords for this news article include: Waltham, Massachusetts, United States, North and Central America, Vascular Diseases and Conditions, Heart Disorders and Diseases, Myocardial Infarction, Myocardial Ischemia, Cardiovascular, Health Policy, Heart Disease, Heart Attack, Cardiology, Medicare, Evidera.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC